• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Endocrinology and Metabolism >Drug prescription patterns and cost analysis of diabetes therapy in India: Audit of an endocrine practice
【24h】

Drug prescription patterns and cost analysis of diabetes therapy in India: Audit of an endocrine practice

机译：印度糖尿病治疗的药物处方模式和费用分析：内分泌实践的审计

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Drug therapy in diabetes care along the duration of diabetes has been documented scarcely in literature, especially from Indian subcontinent. An audit of an endocrine practice from New Delhi was conducted to understand the current diabetes practice and its direct cost to the patient. Aims: The aim of this study was to analyze the current trend in the use of antidiabetes as well as other drugs for comorbidities along the duration of diabetes. The study also aimed to analyze the direct drug cost to patients. Settings and Design: Retrospective cross-sectional study. Subjects and Methods: Data captured in clinic electronic medical records of an endocrine practice was analyzed. Statistical Analysis Used: Data was analyzed descriptively using machine learning codes on python platform. Results: Records of 489 people who attended the clinic during the 6-month period were retrieved. Data of 403 people with diabetes were analyzed after exclusion of incomplete data. Use of antidiabetic drug increased from 1.44 (0.78) [mean (standard deviation)] in people with a duration of diabetes 5 years to 3.18 (1.05) in people with 20+ years of diabetes. The mean number of antidiabetic drug usage seems to plateau at 15 years of diabetes. About 46% of people with 20+ years of diabetes required insulin therapy. Prescription patterns involving a combination of different drug classes in patients were also analyzed. The cost of diabetes therapy increases linearly along the duration of diabetes. Conclusion: This study provides valuable insights on temporal prescription patterns of antidiabetic drugs from an endocrine practice. Metformin remains the most preferred drug across the entire duration of diabetes. Dipeptidyl peptidase-4 inhibitors seem to be fast catching up with sulfonylureas as a second-line treatment after metformin. After 20 years or more of diabetes duration, 46% people would require insulin for glycemic control.
机译：文献中很少有关于糖尿病持续期间糖尿病护理中药物治疗的文献报道，特别是在印度次大陆。对新德里的内分泌实践进行了审核，以了解当前的糖尿病实践及其对患者的直接费用。目的：本研究的目的是分析在糖尿病持续期间使用抗糖尿病药和其他药物治疗合并症的趋势。该研究还旨在分析患者的直接药物费用。设置和设计：回顾性横断面研究。受试者与方法：分析在临床电子病历中捕获的内分泌实践数据。使用的统计分析：使用python平台上的机器学习代码对数据进行描述性分析。结果：检索了在六个月内到诊所就诊的489人的记录。排除不完整数据后，对403名糖尿病患者的数据进行了分析。糖尿病持续时间<5年的人使用抗糖尿病药的比例从1.44（0.78）[平均值（标准差）]增加到糖尿病20年以上的人的3.18（1.05）。糖尿病15年后，抗糖尿病药物的平均使用量似乎处于稳定状态。大约20％的20岁以上糖尿病患者需要胰岛素治疗。还分析了患者中涉及不同药物类别组合的处方模式。糖尿病治疗的费用随着糖尿病的持续时间呈线性增加。结论：这项研究从内分泌实践中获得了有关抗糖尿病药物的时间处方模式的宝贵见解。在整个糖尿病期间，二甲双胍仍然是最优选的药物。在二甲双胍之后，二肽基肽酶-4抑制剂似乎正在迅速被磺酰脲类追赶，成为二线治疗药物。糖尿病持续20年或更长时间后，有46％的人需要胰岛素来控制血糖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号